Lv3
326 积分 2024-11-04 加入
Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma
8小时前
待确认
A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer
2天前
已完结
A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2− advanced breast cancer
8天前
已完结
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study
8天前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
8天前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
23天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1个月前
已完结
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy
4个月前
已关闭
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
4个月前
已完结
皖公网安备34019202002308
